Lead Product(s) : Alphamedix
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Oranomed
Deal Size : Inapplicable
Deal Type : Inapplicable
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
Details : Alphamedix is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroendocrine Tumors.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 10, 2021
Lead Product(s) : Alphamedix
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Oranomed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alphamedix
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Oranomed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET
Details : Alphamedix is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroendocrine Tumors.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 15, 2018
Lead Product(s) : Alphamedix
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Oranomed
Deal Size : Inapplicable
Deal Type : Inapplicable